The FDA has approved the use of Schering-Plough's desloratadine (Clarinex) syrup for the relief of symptoms of seasonal allergic rhinitis in children 2 years of age and older and perennial allergic rhinitis and chronic idiopathic urticaria in children as young as 6 months of age.
Adverse events in children 6 through 11 years of age were similar for groups receiving desloratadine syrup and placebo. In patients 6 months through 5 years of age, the most frequently seen adverse events were upper respiratory tract infection, diarrhea, fever, urinary tract infection, varicella, irritability, and coughing.